The British Heart Foundation has estimated that approximately 620,000 people in the UK are potentially carrying a faulty gene that puts them at high risk sudden death, but the foundation warns majority of carriers are unaware. The charity also noted that an accurate figure could be much higher due to under diagnosis and undiscovered faulty
Roche’s Tecentriq has scored another positive opinion. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently accepted the immunotherapy drug into the Early Access to Medicines Scheme (EAMS) for the treatment advanced bladder cancer. The decision means that patients suffering from bladder cancer could have access to the drug while it awaits decision from
AstraZeneca has expanded a late-stage trial that assess a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy. The Phase III MYSTIC trial was originally designed to assess the benefit of durvalumab monotherapy and a combination of durvalumab
Allergan has stepped into the field of Parkinson’s disease with an option to acquire US-based neurodegenerative research group Lysosomal Therapeutics (LTI). LTI-291, LTI’s lead programme, is designed to stimulate the activity of glucocerebrosidase (GCase) in the brain, which is reduced in many lysosomal storage diseases because of mutations in the GBA1 gene.
The human body has a built-in army to help combat against disease, the immune system. In addition to fighting off bacteria and viruses it can also help combat tumours. That’s why researchers are attempting to rally these cells to treat cancer, leading to some significant advances being made over previous years.
A drug that ‘reinvigorates the immune system’ can extend the lives of lung cancer patients with reduced side effects, according to preliminary results from a late stage clinical trial. “This is another great example of how research into the immune system can deliver powerful new treatments” – Professor Peter Johnson, Cancer Research UK. Patients with
Chief executive of NHS England, Simon Stevens, has unveiled the first fraction of hospitals that will benefit from a major national investment in NHS radiotherapy machines. Fifteen hospitals in areas where there is greatest need have now been selected to receive new LINAC linear (accelerator) machines, as part of a £130-million investment in radiotherapy
To raise awareness during Mouth Cancer Action Month, Cancer Research UK (CRUK) has released figures of an analysis that reveals the rate of oral cancer has risen by 68% in men and women of all ages over the last 20 years. Annual cases in men under 50 have climbed from 340 to around 640, a
Doctors in England have prescribed 2.2 million less antibiotics between 2014 to 2015. Data from Public Health England has shown a significant reduction of 40.7 million to 38.5. A report by the ‘English Surveillance Programme for Antimicrobial Utilisation and Resistance’ (ESPAUR) stated the 4.3 percent decline in antibiotic prescriptions has been noted to be the
According to a recent study by the Canadian Medical Association Journal (CMAJ), patients with chronic obstructive pulmonary disease (COPD) would benefit greatly if pulmonary function testing was used more consistently when diagnosing the condition. COPD is currently the third principal cause of death worldwide and affects over 10% of adults. At the moment, testing airflow